Addressing disparities in biologic drug development in the United States

Key words

Racial and ethnic minorities are underrepresented in clinical trials of mAbs (“biologics”) for allergic diseases, but this is not due to a paucity of minorities with allergic diseases.

Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma.